Clinical trials
Hemophilia A clinical trials
Below are recruiting hemophilia a clinical trials, each written for real people, not researchers. We’re tracking 87 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04728841Recruiting
Gene therapy trial for Chinese hemophilia A
This trial tests a one-time gene therapy treatment (GS001) to help people with hemophilia A make more of the clotting factor they lack. If it works and is safe for you, it could improve how well blood clots form over time.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05849740RecruitingPhase 4
CD38 antibody plus steroid for acquired hemophilia A
This trial studies whether a CD38-targeting antibody together with corticosteroids can improve outcomes in acquired hemophilia A. It is an “exploratory” Phase 4 study, meaning the goal is to learn more about safety and effectiveness in real-world patients.
TianjinAges 18 years+ - NCT06700096RecruitingPhase 3
Testing a new drug for adults with severe hemophilia B
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
ChelyabinskAges 18 years+ - NCT06550882Recruiting
Study of Obizur for adults with acquired hemophilia A in South Korea
This study is for adults in South Korea with acquired hemophilia A, a rare bleeding disorder. It tests a drug called Obizur to see how well it works for people who need it to control bleeding.
SeoulAges 18 years+ - NCT06379789RecruitingPhase 1/Phase 2
Gene therapy for severe hemophilia B
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
Phoenix, ArizonaAges 2 years+ - NCT06222697Recruiting
Safety study of Jivi for hemophilia A in Korea
This study is checking the safety of Jivi (a Factor VIII medicine) when used in normal medical care for people with hemophilia A in Korea. It is for anyone 12 or older who has used Factor VIII before or is starting Jivi as part of their regular treatment.
Multiple LocationsAges 12 years+ - NCT06145373RecruitingPhase 4
Fitusiran for preventing bleeds in severe hemophilia A
This study tests a new medicine called fitusiran to help prevent bleeding episodes in people with severe hemophilia A who are already receiving emicizumab. It may offer an additional treatment option for those with or without inhibitors.
Los Angeles, CaliforniaAges 12 years+ - NCT06147414Recruiting
Blood test for genetic disorders in pregnancy
This study tests a safer blood test to check for certain genetic disorders during pregnancy, instead of an invasive procedure like amniocentesis. It's for pregnant women who are at risk of passing on a known genetic condition.
ParisAges 18 years+ - NCT06111638RecruitingPhase 2/Phase 3
Gene therapy for severe hemophilia A
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06008938Recruiting
Study tracking HEMGENIX for hemophilia B
This study watches how well HEMGENIX works and how safe it is for people with hemophilia B who are getting the treatment. It also compares data from adults on standard factor IX shots.
Rochester, New YorkAges 18 years+ - NCT06003387RecruitingPhase 3
Gene therapy for hemophilia B with AAV5 antibodies
This trial tests a gene therapy called CSL222 for adults with hemophilia B who have antibodies against the AAV5 virus used to deliver the therapy. It aims to see if the treatment is safe and effective even when these antibodies are present.
San Diego, CaliforniaAges 18 years+ - NCT05987449RecruitingPhase 1/Phase 2
Study of NXT007 for people with hemophilia A
This study tests a new medicine called NXT007 for people with moderate or severe hemophilia A. The goal is to see if it is safe, well-tolerated, and can help prevent or reduce bleeding episodes, possibly reducing the need for standard treatments. You may be able to join if you have hemophilia A with or without inhibitors and meet other health requirements.
Sacramento, CaliforniaAges 2–59 - NCT05962398Enrolling by invitation
Follow-up study for men previously treated with CSL222
This study checks long-term safety and outcomes in men with hemophilia B who previously received CSL222. It may help your care team better understand how well the treatment lasts over many years.
Phoenix, ArizonaAges 18 years+ - NCT05768386Enrolling by invitation
Long-term follow-up for severe hemophilia A after BMN 270 study
This study checks how people with severe hemophilia A are doing over time after joining a previous BioMarin study of BMN 270. It helps researchers understand long-term safety and outcomes and may support your ongoing care plan.
Los Angeles, CaliforniaAges 18 years+ - NCT05022459Recruiting
Prevent bleeding in kids with Hemophilia A who play sports
This study compares two ways to prevent bleeding in people with Hemophilia A while they play sports. It looks at whether factor VIII or emicizumab prophylaxis helps reduce bleeding during higher-risk sports activities.
Little Rock, ArkansasAges 6–19 - NCT04023019Recruiting
Hemophilia A trial for people with FVIII inhibitors
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
Atlanta, GeorgiaAges Any age - NCT06941870RecruitingPhase 4
Prevention treatment for hemophilia A with joint swelling
This study tests a preventive treatment called efanesoctocog alfa to see if it can help people with moderate to severe hemophilia A who have joint swelling (synovial hypertrophy). It aims to reduce joint bleeding and improve joint health.
Los Angeles, CaliforniaAges 12 years+ - NCT05629130Recruiting
Blocking blood vessel procedures for bleeding-related joint inflammation
This study looks at whether a “blocking” procedure (embolization) can improve long-lasting joint inflammation caused by inherited bleeding disorders. It focuses on people with joint lining inflammation from repeated bleeding into the joint.
São PauloAges Any age - NCT07867821Recruiting
Finding new markers in hemophilia joint damage
This study looks at tissue from joints affected by hemophilia to find new markers that could help understand and treat joint damage. It is for people with severe hemophilia who need a joint procedure like a fluid removal, synovectomy, or joint replacement.
MilanAges Any age - NCT07723560Recruiting
Surgery study for hemophilia A patients using Altuvoct
This study looks at how people with hemophilia A do when they have surgery while using the medicine Altuvoct (efanesoctocog alfa). It helps doctors learn more about surgical practices for this condition.
BronAges Any age - NCT07681089RecruitingPhase 2
Foscenvivint for HIV/HCV cirrhosis with hemophilia
This trial tests a drug called foscenvivint for people with hemophilia and liver cirrhosis caused by both HIV and hepatitis C (already treated). The study aims to see if it can help improve liver health.
Sapporo, HokkaidoAges 18–79 - NCT07545395RecruitingPhase 3
Safety study of KN057 blood clot prevention in hemophilia
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Tianjin, Tianjin MunicipalityAges 12–65 - NCT07452575Enrolling by invitation
3D ultrasound to check ankle bleeds in hemophilia
This study tests whether a 3D ultrasound can better see and check ankle joint bleeding in people with hemophilia or other bleeding disorders. It may help doctors find and treat ankle bleeds more quickly, which could protect the joint.
Toronto, OntarioAges 5–18 - NCT07437404RecruitingPhase 3
Testing SCT800 for previously untreated severe hemophilia A
This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.
Beijing, Beijing MunicipalityAges Up to 6 years
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hemophilia a?
- Yes. Clin2 currently lists 87 recruiting hemophilia a studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hemophilia a trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hemophilia a trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.